NASDAQ · OVID
Healthcare · Biotechnology
$2.37
Up+$0.03 (+1.28%)
Updated Oct 7, 2026, 3:44 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OVID
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
OVID closed at $2.37 after 21 trading sessions, down 13.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.42 | $2.44 | $2.27 | $2.37 | 1.74M |
| Oct 5, 2026 | $2.38 | $2.47 | $2.29 | $2.34 | 1.2M |
| Oct 2, 2026 | $2.47 | $2.48 | $2.33 | $2.38 | 2.17M |
| Oct 1, 2026 | $2.49 | $2.53 | $2.42 | $2.43 | 1.35M |
| Sep 30, 2026 | $2.54 | $2.605 | $2.48 | $2.49 | 1.44M |
| Sep 29, 2026 | $2.47 | $2.54 | $2.42 | $2.54 | 1.16M |
| Sep 28, 2026 | $2.40 | $2.49 | $2.35 | $2.46 | 1.19M |
| Sep 25, 2026 | $2.49 | $2.51 | $2.40 | $2.40 | 1.36M |
| Sep 24, 2026 | $2.54 | $2.54 | $2.405 | $2.495 | 1.53M |
| Sep 23, 2026 | $2.75 | $2.75 | $2.44 | $2.57 | 2.64M |
| Sep 22, 2026 | $2.76 | $2.845 | $2.714 | $2.76 | 3.74M |
| Sep 21, 2026 | $2.73 | $2.76 | $2.65 | $2.71 | 1.18M |
| Sep 18, 2026 | $2.68 | $2.73 | $2.63 | $2.69 | 5.9M |
| Sep 17, 2026 | $2.73 | $2.77 | $2.66 | $2.70 | 1.99M |
| Sep 16, 2026 | $2.72 | $2.765 | $2.65 | $2.68 | 1.43M |
| Sep 15, 2026 | $2.73 | $2.745 | $2.63 | $2.71 | 988.55K |
| Sep 14, 2026 | $2.755 | $2.795 | $2.6901 | $2.74 | 1.2M |
| Sep 11, 2026 | $2.73 | $2.73 | $2.64 | $2.69 | 1.15M |
| Sep 10, 2026 | $2.68 | $2.70 | $2.61 | $2.63 | 1.4M |
| Sep 9, 2026 | $2.74 | $2.781 | $2.685 | $2.70 | 1.26M |
| Sep 8, 2026 | $2.75 | $2.81 | $2.73 | $2.75 | 1.15M |
The latest Smart Investors Daily articles mentioning OVID.
Company
Market Activity
Research & News
OVID research
Company profile and research snapshot.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Apr 15, 2026 | Wedbush | Outperform | — |
| Apr 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the update to lay out progress on two clinical programs, a leadership shakeup, and a deal that hands off one of its […]
Benzinga · Sep 11, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.
Yahoo · Sep 3, 2026
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ETH.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET Webcasts of the pre
Yahoo · Aug 13, 2026
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OVID.
